These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20417967)

  • 1. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
    Fesler MJ; Richart JM; Petruska PJ
    Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
    [No Abstract]   [Full Text] [Related]  

  • 2. Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.
    Fesler MJ
    Leuk Res; 2011 Mar; 35(3):e21-2. PubMed ID: 21144585
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
    Winkler J; Rech D; Kallert S; Rech J; Meidenbauer N; Roesler W; Mackensen A
    Leuk Res; 2010 Oct; 34(10):e270-2. PubMed ID: 20627386
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
    Lee SH; Paietta E; Racevskis J; Wiernik PH
    Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
    Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
    Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
    Schroeder T; Zohren F; Saure C; Bruns I; Czibere A; Safaian NN; Fenk R; Haas R; Kobbe G
    Acta Haematol; 2010; 124(3):153-9. PubMed ID: 20938170
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.
    Martínez-López J; Castro N; Rueda D; Canal A; Grande C; Ayala R
    Br J Haematol; 2012 Aug; 158(4):555-8. PubMed ID: 22686329
    [No Abstract]   [Full Text] [Related]  

  • 9. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
    Metzelder SK; Schroeder T; Finck A; Scholl S; Fey M; Götze K; Linn YC; Kröger M; Reiter A; Salih HR; Heinicke T; Stuhlmann R; Müller L; Giagounidis A; Meyer RG; Brugger W; Vöhringer M; Dreger P; Mori M; Basara N; Schäfer-Eckart K; Schultheis B; Baldus C; Neubauer A; Burchert A
    Leukemia; 2012 Nov; 26(11):2353-9. PubMed ID: 22504140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
    Sorà F; Chiusolo P; Metafuni E; Bellesi S; Giammarco S; Laurenti L; Ausoni G; Zini G; Bayer AJ; Mario B; Leone G; Sica S
    Leuk Res; 2011 Mar; 35(3):422-3. PubMed ID: 21093053
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
    Watt TC; Cooper T
    Pediatr Blood Cancer; 2012 Oct; 59(4):756-7. PubMed ID: 22052552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
    Safaian NN; Czibere A; Bruns I; Fenk R; Reinecke P; Dienst A; Haas R; Kobbe G
    Leuk Res; 2009 Feb; 33(2):348-50. PubMed ID: 18573526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
    Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK; Grundler R; Peschel C; Duyster J
    Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
    Auclair D; Miller D; Yatsula V; Pickett W; Carter C; Chang Y; Zhang X; Wilkie D; Burd A; Shi H; Rocks S; Gedrich R; Abriola L; Vasavada H; Lynch M; Dumas J; Trail PA; Wilhelm SM
    Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
    Metzelder S; Wang Y; Wollmer E; Wanzel M; Teichler S; Chaturvedi A; Eilers M; Enghofer E; Neubauer A; Burchert A
    Blood; 2009 Jun; 113(26):6567-71. PubMed ID: 19389879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
    Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD
    Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Wiernik PH
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics.
    Mori M; Sprague J
    Leuk Res; 2012 Jan; 36(1):e1-3. PubMed ID: 21996560
    [No Abstract]   [Full Text] [Related]  

  • 20. FLT3 inhibitors for acute myeloid leukemia.
    Lancet JE
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.